Skip to search formSkip to main contentSkip to account menu

ADR-529

Known as: ADR 529, ADR529 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DexrazoxaneDexrazoxane hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529
SummaryThe purpose of this study was to evaluate the optimal timing of ADR-529 administration to protect rats treated with… 
1996
1996
Long-Lasting Effect of Dexrazoxane Against Anthracycline Cardiotoxicity in Rats
The long-lasting protective effect of dexrazoxane (ADR-529) against doxorubicin- and epirubicin-induced cardiotoxicity was… 
Highly Cited
1992
Highly Cited
1992
Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in… 
Highly Cited
1992
Highly Cited
1992
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
BACKGROUND Although doxorubicin is an anticancer agent with a wide spectrum of activity, therapy with this anthracycline must… 
1992
1992
In vitro effects of three iron chelators on mitogen-activated lymphocytes: identification of differences in their mechanisms of action.
1992
1992
In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex.
ADR-529 protects against anthracycline cardiotoxicity, possibly by preventing free radical induction. We hypothesize that this… 
Review
1991
Review
1991
ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.
Anthracyclines are anticancer agents that are effective in a wide range of tumors. Unfortunately, their activity is limited by… 
Review
1991
Review
1991
Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity.
1990
1990
dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase…
Iron-catalyzed free radical reactions, such as the peroxidation of membrane lipids or the inactivation of critical enzymes, have… 
Review
1990
Review
1990
Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)